Navigation Links
Promising drug combination may help those with ocular melanoma that has spread
Date:9/4/2007

DURHAM, N.C. -- A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.

The drugs -- decitabine, which can turn on certain genes in cancer cells, and interferon gamma, an immune system protein -- may work together to cause cancer cell death.

Metastatic uveal melanoma, or melanoma that originates in the eye and spreads to other parts of the body, has been very difficult to treat, in fact there have been no effective therapies to date, said Jared Gollob, M.D., a medical oncologist at Duke and lead investigator on the study. This study could lead to a very promising new therapy for patients who previously had very little hope.

The researchers published their findings in the September 1, 2007 issue of the journal Clinical Cancer Research. The study was funded by the National Institutes of Health.

This pre-clinical study came on the heels of previous lab work examining proteins called interferons, which originate from immune system cells. These proteins were shown to boost immune function and directly affect melanoma cells, inhibiting their growth and accelerating their death, Gollob said.

We also knew that a drug called decitibine could turn on genes that had been turned off in cancer cells, so we speculated that if we combined decitabine and interferon gamma, we might see heightened cell death, and thats exactly what happened, Gollob said. Decitabine may turn on a certain gene, called S100A2, that is, in turn, able to increase the sensitivity of cancer cells to interferon gamma, he said.

Researchers used human cell lines, derived from patients who had been diagnosed with uveal melanoma, for this study. The next step will be a clinical study looking at the effectiveness of this drug combination in human subjects, Gollob said.

Uveal melanoma affects about 5,000 to 10,000 people each year in the United States. Unlike its counterpart on the skin, there are no known risk factors, Gollob said.

There are really no truly effective treatments for this devastating disease, he said. So this study really is a promising step toward finding a therapy that can really help these patients.

Uveal melanoma originates in the colored part of the eye, and symptoms include changes in vision, such as blurriness. If found early, it can be treated with radiation or with removal of the eye. When it spreads, uveal melanoma is typically unresponsive to standard treatment regimens, such as chemotherapy, Gollob said. Life expectancy once the disease has spread is about six to ten months, on average, he said.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. A promising treatment for wart removal
4. Hepatitis shots is promising
5. Promising Treatment for Diabetes
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Tel Aviv (PRWEB) , ... May 31, 2016 ... ... in the May 4, 2016 Cool Vendors in Security Infrastructure Protection report by ... areas and publishes a series of research reports evaluating these innovative vendors and ...
(Date:5/31/2016)... PLAINSBORO, N.J. (PRWEB) , ... May 31, 2016 ... ... digital and print media enterprise focused on patients with cancer, has added ... provide readers and website visitors with more timely content on continuing successful careers ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader in ... original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The new ... with various federal regulations and reforms. , Navigating the new health reforms can ...
(Date:5/29/2016)... ... 29, 2016 , ... Whole Health Supply is happy to announce a new ... available to the public. This is an unusual clipper because it opens to a ... , Everything about this product is concentrated on ease of use, functionality and durability. ...
(Date:5/28/2016)... ... ... May 26, 2016- In search of the K. Warriors, Shaolin Institute is ... Warriors” on June 4, 2016 at Ashbury Hotel and Suites 600 West Interstate 65 ... by Shaolin Institute and sanctioned by KSF (Kungfu Sanda Federation), This is the 28th ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... 31, 2016 RnRMarketResearch.com adds "Asthma ... comparative analysis of Asthma therapy at various stages, therapeutics ... of administration (RoA) and molecule type, along with latest ... reviews key players involved in the therapeutic development for ... Complete report on H1 2016 pipeline review ...
(Date:5/30/2016)... 30, 2016 On 28 May, 194 ... by 2030. At the 69 th World Health Assembly, ... Hepatitis Strategy, signalling the greatest global commitment in viral hepatitis ... eliminating hepatitis B and C by 2030 and includes a ... reduce annual deaths by 65% and increase treatment to 80%, ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( NASDAQ: DRIO ... that the Company,s Chief Financial Officer, Zvi Ben-David ... 1-2 in New York, NY and ... Los Angeles, CA. During his ... including the U.S. FDA Clearance and commercial launch of the ...
Breaking Medicine Technology: